| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Rheumatology Research Laboratory and Advanced Therapeutics,* University Medical Center Nijmegen, Nijmegen, The Netherlands; and the Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan
Interleukin (IL)-18 is a member of the IL-1 family of proteins that exerts proinflammatory effects and is a pivotal cytokine for the development of Th1 responses. The goal of the present study was to investigate whether IL-18 induces joint inflammation and joint destruction directly or via induction of other cytokines such as IL-1 and tumor necrosis factor (TNF). To this end we performed both in vitro and in vivo kinetic studies. For in vivo IL-18 exposure studies C57BL/6, TNF-deficient, and IL-1-deficient mice were injected intra-articularly with 1.107 pfu mIL-18 adenovirus followed by histopathological examination. Local overexpression of IL-18 resulted in pronounced joint inflammation and cartilage proteoglycan loss in control mice. Of high interest, IL-18 gene transfer in IL-1-deficient mice did not show cartilage damage, although joint inflammation was similar to that in wild-type animals. Overexpression of IL-18 in TNF-deficient mice showed that TNF was partly involved in IL-18-induced joint swelling and influx of inflammatory cells, but cartilage proteoglycan loss occurred independent of TNF. In vitro cartilage degradation by IL-18 was found after a 72-hour culture period. Blocking of IL-1 with IL-1Ra or an ICE-inhibitor resulted in complete protection against IL-18-mediated cartilage degradation. The present study demonstrated that IL-18 induces joint inflammation independently of IL-1. In addition, we showed that IL-1ß generation, because of IL-18 exposure, was essential for marked cartilage degradation both in vitro and in vivo. These findings implicate that IL-18, in contrast to TNF, contributes through separate pathways to joint inflammation and cartilage destruction.
This article has been cited by other articles:
 |
|
 |
|
  H. P. Carroll, V. Paunovic, and M. Gadina Crossed signals: the role of interleukin-15 and -18 in autoimmunity Rheumatology, July 10, 2008; (2008) ken257v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Dai, Z.-Z. Shan, H. Xu, and K. Nishioka Cellular targets of interleukin-18 in rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway J. Immunol., July 1, 2006; 177(1): 234 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. B. Joosten, M. G. Netea, S.-H. Kim, D.-Y. Yoon, B. Oppers-Walgreen, T. R. D. Radstake, P. Barrera, F. A. J. van de Loo, C. A. Dinarello, and W. B. van den Berg IL-32, a proinflammatory cytokine in rheumatoid arthritis PNAS, February 28, 2006; 103(9): 3298 - 3303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kim, S. Lee, S. Suvas, and B. T. Rouse Application of Plasmid DNA Encoding IL-18 Diminishes Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., July 1, 2005; 175(1): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
